Is Oragenics, Inc. overvalued or undervalued?

As of 12 August 2016, the valuation grade for Oragenics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued given its negative financial metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 3.06, and an EV to EBITDA of -0.22. The return on equity (ROE) is alarmingly low at -1033.41%, reflecting severe operational challenges.
In comparison to its peers, Oragenics, Inc. shows a less favorable position; for instance, Lexaria Bioscience Corp. has a P/E of -2.0847 and an EV to EBITDA of -1.4100, while Cyclerion Therapeutics, Inc. has a P/E of -3.0156 and an EV to EBITDA of -1.8268, both indicating similar struggles within the industry. The company's stock has underperformed significantly against the S&P 500, with a year-to-date decline of 67.87% compared to the index's modest gain of 2.44%. Overall, the combination of these factors strongly suggests that Oragenics, Inc. is overvalued.